Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy

Chemotherapy-induced nausea and vomiting is a common problem during cancer treatment, especially in breast cancer patients with anthracycline/cyclophosphamide (ас) chemotherapy. Netupitant/palonosetron (NEPA; Akynzeo®) is a fixed-dose combination of two drugs (netupitant, a neurokinin 1 receptor ant...

Full description

Saved in:
Bibliographic Details
Main Authors: A. G. Kedrova, A. I. Berishvili
Format: Article
Language:Russian
Published: ABV-press 2023-10-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/1138
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849241502528569344
author A. G. Kedrova
A. I. Berishvili
author_facet A. G. Kedrova
A. I. Berishvili
author_sort A. G. Kedrova
collection DOAJ
description Chemotherapy-induced nausea and vomiting is a common problem during cancer treatment, especially in breast cancer patients with anthracycline/cyclophosphamide (ас) chemotherapy. Netupitant/palonosetron (NEPA; Akynzeo®) is a fixed-dose combination of two drugs (netupitant, a neurokinin 1 receptor antagonist; and palonosetron, a serotonin 3 receptor antagonist) which target two diferent signalling pathways involved in the induction of vomiting. Approved for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting in adults, netupitant/palonosetron is given orally or via intravenous infusion as a single dose prior to chemotherapy. In clinical trials, high proportions of patients who received netupitant/palonosetron (used in combination with the corticosteroid dexamethasone) prior to chemotherapy reported no vomiting, no requirement for rescue medication, and no signifcant nausea in the 5 days post chemotherapy. Both the oral and intravenous formulations of the drug combination are well tolerated. Thus, netupitant/palonosetron is a simple, convenient and efective drug combination for the prevention of acute and delayed xhemotherapy-induced nausea and vomiting in patients receiving chemotherapy that has a moderate to high emetogenic potential.
format Article
id doaj-art-b838d9da32ad4bc99406484b1b2a30b6
institution Kabale University
issn 1994-4098
1999-8627
language Russian
publishDate 2023-10-01
publisher ABV-press
record_format Article
series Опухоли женской репродуктивной системы
spelling doaj-art-b838d9da32ad4bc99406484b1b2a30b62025-08-20T04:00:08ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272023-10-01193546210.17650/1994-4098-2023-19-3-54-62813Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapyA. G. Kedrova0A. I. Berishvili1Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Biomedical Agency of the Russian Federation; Federal Research and Clinical Center, Federal Biomedical AgencyFederal Research and Clinical Center, Federal Biomedical AgencyChemotherapy-induced nausea and vomiting is a common problem during cancer treatment, especially in breast cancer patients with anthracycline/cyclophosphamide (ас) chemotherapy. Netupitant/palonosetron (NEPA; Akynzeo®) is a fixed-dose combination of two drugs (netupitant, a neurokinin 1 receptor antagonist; and palonosetron, a serotonin 3 receptor antagonist) which target two diferent signalling pathways involved in the induction of vomiting. Approved for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting in adults, netupitant/palonosetron is given orally or via intravenous infusion as a single dose prior to chemotherapy. In clinical trials, high proportions of patients who received netupitant/palonosetron (used in combination with the corticosteroid dexamethasone) prior to chemotherapy reported no vomiting, no requirement for rescue medication, and no signifcant nausea in the 5 days post chemotherapy. Both the oral and intravenous formulations of the drug combination are well tolerated. Thus, netupitant/palonosetron is a simple, convenient and efective drug combination for the prevention of acute and delayed xhemotherapy-induced nausea and vomiting in patients receiving chemotherapy that has a moderate to high emetogenic potential.https://ojrs.abvpress.ru/ojrs/article/view/1138netupitantpalonosetronnepaakynzeochemotherapybreast cancervomitingnauseaprevention
spellingShingle A. G. Kedrova
A. I. Berishvili
Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy
Опухоли женской репродуктивной системы
netupitant
palonosetron
nepa
akynzeo
chemotherapy
breast cancer
vomiting
nausea
prevention
title Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy
title_full Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy
title_fullStr Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy
title_full_unstemmed Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy
title_short Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy
title_sort netupitant palonosetron nepa akynzeo r combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy
topic netupitant
palonosetron
nepa
akynzeo
chemotherapy
breast cancer
vomiting
nausea
prevention
url https://ojrs.abvpress.ru/ojrs/article/view/1138
work_keys_str_mv AT agkedrova netupitantpalonosetronnepaakynzeocombinationinpreventionofthenauseaandvomitinginpatientswithbreastcancerreceivinganthracyclinbasedchemotherapy
AT aiberishvili netupitantpalonosetronnepaakynzeocombinationinpreventionofthenauseaandvomitinginpatientswithbreastcancerreceivinganthracyclinbasedchemotherapy